IRIS
ZUCALI, PAOLO ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.388
AS - Asia 4.904
EU - Europa 1.560
SA - Sud America 1.306
AF - Africa 275
Continente sconosciuto - Info sul continente non disponibili 20
OC - Oceania 8
AN - Antartide 1
Totale 14.462
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.211
SG - Singapore 3.035
BR - Brasile 1.070
CN - Cina 653
VN - Vietnam 605
FI - Finlandia 329
IE - Irlanda 290
IT - Italia 206
NG - Nigeria 191
DE - Germania 150
FR - Francia 128
HK - Hong Kong 128
CA - Canada 113
GB - Regno Unito 112
AR - Argentina 96
SE - Svezia 93
IN - India 81
TR - Turchia 81
NL - Olanda 72
BD - Bangladesh 51
IQ - Iraq 47
EC - Ecuador 44
MX - Messico 37
ID - Indonesia 34
IL - Israele 32
RU - Federazione Russa 29
CO - Colombia 27
JP - Giappone 23
PL - Polonia 23
UA - Ucraina 23
ES - Italia 21
PK - Pakistan 21
ZA - Sudafrica 20
CL - Cile 19
MA - Marocco 17
PY - Paraguay 16
VE - Venezuela 15
BE - Belgio 14
EG - Egitto 14
EU - Europa 13
IR - Iran 12
UZ - Uzbekistan 12
TW - Taiwan 11
AE - Emirati Arabi Uniti 10
DZ - Algeria 9
JO - Giordania 9
DO - Repubblica Dominicana 8
LT - Lituania 8
SA - Arabia Saudita 8
UY - Uruguay 8
A2 - ???statistics.table.value.countryCode.A2??? 7
AU - Australia 7
CH - Svizzera 7
NP - Nepal 7
PE - Perù 7
PH - Filippine 7
CZ - Repubblica Ceca 6
KE - Kenya 6
MY - Malesia 6
PT - Portogallo 6
TN - Tunisia 6
AT - Austria 5
ET - Etiopia 5
JM - Giamaica 5
AL - Albania 4
AZ - Azerbaigian 4
GR - Grecia 4
LB - Libano 4
LV - Lettonia 4
SN - Senegal 4
BA - Bosnia-Erzegovina 3
DK - Danimarca 3
GE - Georgia 3
HN - Honduras 3
OM - Oman 3
RO - Romania 3
BG - Bulgaria 2
BH - Bahrain 2
BO - Bolivia 2
BY - Bielorussia 2
HU - Ungheria 2
KZ - Kazakistan 2
MK - Macedonia 2
NI - Nicaragua 2
NO - Norvegia 2
PR - Porto Rico 2
PS - Palestinian Territory 2
QA - Qatar 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
AQ - Antartide 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
CR - Costa Rica 1
EE - Estonia 1
GA - Gabon 1
GF - Guiana Francese 1
GI - Gibilterra 1
Totale 14.446
Salva come PNG Salva come JPEG
Città #
Singapore 1.355
Wilmington 915
Chandler 558
Ashburn 476
The Dalles 441
San Mateo 378
Shanghai 341
Dallas 327
Helsinki 320
Dublin 290
Ann Arbor 262
San Jose 260
Ho Chi Minh City 228
Benin City 190
Lawrence 187
Princeton 187
Leawood 179
New York 174
Beijing 143
Hanoi 138
Woodbridge 121
Hong Kong 118
Paris 105
São Paulo 105
Fairfield 101
Boardman 98
Amsterdam 69
Milan 67
Toronto 59
Los Angeles 53
Kocaeli 52
London 49
Phoenix 42
Santa Clara 40
Rio de Janeiro 32
Seattle 32
Da Nang 31
Council Bluffs 29
San Diego 25
Curitiba 24
Redwood City 24
Baghdad 21
Belo Horizonte 21
Norwalk 21
Brasília 20
Warsaw 20
Chennai 19
Porto Alegre 18
Columbus 17
Haiphong 17
Montreal 16
Naples 16
Stockholm 16
Brussels 14
Munich 14
Thái Bình 14
Guayaquil 13
Monmouth Junction 13
Orem 13
Salvador 13
Tokyo 13
Boston 12
Fortaleza 12
Manchester 12
Quito 12
Brooklyn 11
Campinas 11
Carapicuíba 11
Frankfurt am Main 11
Pune 11
Redmond 11
Biên Hòa 10
Buenos Aires 10
Can Tho 10
Dhaka 10
Mexico City 10
Tashkent 10
Ankara 9
Asunción 9
Bắc Ninh 9
Charlotte 9
Denver 9
Istanbul 9
Jakarta 9
Santiago 9
Santo André 9
Vancouver 9
Amman 8
Assago 8
Atlanta 8
Cairo 8
Erbil 8
Falkenstein 8
Guarulhos 8
Houston 8
Johannesburg 8
Andover 7
Buffalo 7
Chicago 7
Hyderabad 7
Totale 9.318
Salva come PNG Salva come JPEG
Nome #
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer 158
Gene methylation in pleural mesothelioma : Correlations with clinico-pathological features and patient’s follow-up 130
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery 124
Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study) 120
VINORELBINE (V) IN PEMETREXED-PRETREATED PATIENTS (PTS) WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 116
721P Ipilimumab and nivolumab compassionate use program in metastatic renal cell carcinoma patients with intermediate or poor IMDC risk score: The large multicenter Italian study 114
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 105
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors 105
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer 103
Treatment of malignant pleural mesothelioma: current status and future directions 103
Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas 101
Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top" 100
Advances in the biology of malignant pleural mesothelioma 100
Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma 98
Digital analysis of intratumoural heterogeneity reveals higher leucocytic infiltrate in VETC (Vessels Encapsulating Tumour Clusters) areas 97
Short schedule of cisplatin and vinorelbine: A dose-finding study in non-small-cell lung cancer 96
Neutrophil to Lymphocyte Ratio (NLR) as predictive factor in patients with metastatic soft tissue sarcoma (STS) treated with trabectedin (T). 96
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial 96
PHASE II STUDY OF THE COMBINATION OF BEVACIZUMAB PLUS PEMETREXED AND CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 94
A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma 92
Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non-Small Cell Lung Cancer Patients Treated with Gefitinib 91
Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: Can it be safely associated with fluorouracil-based chemotherapy? 90
Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors 89
Computed tomography (CT)-derived radiomic features differentiate prevascular mediastinum masses as thymic neoplasms versus lymphomas 89
Activity and safety of trabectedin in patients with sarcomatoid / biphasic malignant pleural mesothelioma (MPM) 88
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors 87
Assessment of tumor response in malignant pleural mesothelioma 87
Irinotecan and raltitrexed: an active combination in advanced colorectal cancer 87
Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [F-18]fluorodeoxyglucose 87
Reproducibility of the WHO classification of thymomas: practical implications 85
Insulin-Like Growth Factor-1 Receptor and Phosphorylated AKT-Serine 473 Expression in 132 Resected Thymomas and Thymic Carcinomas 85
Prophylaxis of central venous catheter-related thrombosis with minidose warfarin: Analysis of its use in 427 cancer patients 84
Changes in shedding of soluble tumor necrosis factor receptors (sR1/R2) and in dynamic MRI as early predictors of outcome with NGR-hTNF 84
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 84
New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma 83
Targeted therapy for thymic epithelial tumors: a new horizon ? Review of the literature and two cases reports 83
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1 in patients with hepatocellular carcinoma 83
Prognostic and predictive role of [F-18]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy 82
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy 82
Expression and mutational status of c-kit in thymic epithelial tumors 80
Response to Sunitinib in an Adult Patient With Rhabdoid Renal Cell Carcinoma 80
Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey 79
Phase II Study of Asparagine-Glycine-Arginine-Human Tumor Necrosis Factor alpha, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma 79
Anti-angiogenic therapies for malignant pleural mesothelioma 78
Malignant mesothelioma-associated inflammatory microenvironment promotes tumor progression via GPNMB 78
Baseline Radiomic CT Features Differentiate Mediastinal Masses As Thymic Neoplasms Or Lymphomas 77
Management of germ cell tumors during the outbreak of the novel coronavirus disease‐19 pandemic: a survey of international expertise centers 77
Precision medicine in Salivary Gland Carcinoma: Insights from breast and prostate cancer 77
Minidose warfarin is associated with a high incidence of International Normalized Ratio elevation during chemotherapy with FOLFOX regimen 76
"One marker does not fit all": additional translational and validation studies are needed to identify faithful predictors of pemetrexed activity in mesothelioma 76
Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): Results of Italian Rames Study 76
Advances in drug treatments for mesothelioma 75
[Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?] 75
Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin 74
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma 74
The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas 73
Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. 73
The Role of Pemetrexed in the Pharmacotherapy of Malignant Pleural Mesothelioma 73
A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors 73
THE ROLE OF THYMIDTYLATE SYNTHASE (TS) AND EXCISION REPAIR CROSS-COMPLEMENTING GROUP 1 (ERCC1) IMMUNOHISTOCHEMICAL EXPRESSION IN MALIGNANT PLEURAL MESOTHELIOMA (MPM) PATIENTS TREATED WITH PEMETREXED AND CARBOPLATIN 72
Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma 72
Antiproliferative effects of novel aliphatic acetogenin analogs against aggressive solid tumor cell lines 72
Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors 72
A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors 72
Positron emission tomography with F18-fluorodeoxyglucose (FDG-PET) in malignant pleural mesothelioma (MPM): Evaluation of response to chemotherapy by quantitative assessment of standardized uptake value (SUV) 71
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients 70
Survival Outcomes in Malignant Pleural Mesothelioma Patients Fit for Surgery According to Type of Procedure and Completeness of Resection 70
Autoimmunity in thymic epithelial tumors: a not yet clarified pathologic paradigm associated with several unmet clinical needs 70
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma 69
Imaging biomarkers in primary brain tumours 69
Intratumoral Switch of Molecular Phenotype and Overall Survival in Muscle Invasive Bladder Cancer 68
Malignant pleural mesothelioma (MPM) evaluation with C-11-methionine PET/CT before and after talc pleurodesis 68
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 68
SAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial 68
Baseline and early change of neutrophil to lymphocyte ratio (bNLR and ΔNLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study 68
Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study 67
Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma 67
Positron emission tomography with F18-fluorodeoxyglucose (FDG-PET) in malignant pleural mesothelioma (MPM): Prediction of response to chemotheraphy by quantitative assessment of standard uptake value (SUV) 67
Morphometric vertebral fractures in patients with castration-resistant prostate cancer undergoing treatment with radium-223: a longitudinal study in the real-life clinical practice. 67
IMPACT OF SOLUBLE TUMOR NECROSIS FACTOR-RECEPTORS (STNF-RS) SHEDDING ON OUTCOME IN PATIENTS TREATED WITH NGR-HTNF 67
A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1 67
Vessels encapsulating tumour clusters (VETC) in renal cell carcinoma (RCC). prognostic role and predictive value to tyrosine kinase inhibitors (TKI) therapy. A Bayesian retrospective clinico-pathological study 67
Biology and management of malignant pleural mesothelioma 66
Bladder metastases of appendiceal mucinous adenocarcinoma: a case presentation 66
Emerging Radiopharmaceuticals in Pet Imaging for Mesothelioma: A Review of [18F]FDG Alternatives 65
PHASE I AND PHARMACODYNAMIC STUDY OF NGR-HTNF ADMINISTERED AT HIGH DOSES IN REFRACTORY PATIENTS WITH SOLID TUMORS 64
Safety and activity of Combined AVElumab with Axitinib in unresectable or metastatic Thymomas B3 and Thymic carcinomas: The CAVEATT study 64
The neural phenotype in invasive urothelial carcinoma patients: Alternative score detection and prognostic implication 64
SNPs in PI3K-PTEN-mTOR and brain metastases in NSCLC--letter 64
EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations 63
Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors 63
Phase II study of Pemetrexed and Carboplatin plus Bevacizumab as first-line therapy in malignant pleural mesothelioma 63
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin 63
Role of SBRT with VMAT technique and FFF beams for lymph-node metastases in oligometastatic patients from genitourinary malignancies 63
Baseline and early change of systemic inflammation index (bSII and ΔSII) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study 63
NGR-hTNF, a vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM): a phase II study 62
Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors 62
Vinorelbine as second or third-line therapy in pemetrexed-pretreated malignant pleural mesothelioma (MPM) patients 62
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma 61
Future developments in the management of malignant pleural mesothelioma 61
Totale 8.028
Salva come PNG Salva come JPEG
Categoria #
all - tutte 100.573
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 100.573
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021424 0 0 0 0 0 0 0 0 0 215 7 202
2021/20221.014 49 29 28 185 15 6 37 128 100 112 290 35
2022/20231.975 408 65 217 169 131 127 6 127 322 224 161 18
2023/20241.345 117 142 244 40 30 183 84 78 27 28 140 232
2024/20252.264 20 70 23 38 68 270 112 187 316 546 292 322
2025/20266.162 917 624 529 921 240 312 1.632 361 375 251 0 0
Totale 14.731